產(chǎn)品中心Cell Resources
聯(lián)系我們CONTACT US
- 400-999-210024小時服務熱線
產(chǎn)品概述
名稱 | H22 (小鼠肝癌細胞) (STR鑒定正確) |
別稱 | Hepatoma-22; Hepatoma 22 |
種屬 | 小鼠 |
生長特性 | 懸浮細胞 |
細胞形態(tài) | 淋巴母細胞樣 |
凍存條件 | 凍存液:55% 基礎培養(yǎng)基+40%FBS+5%DMSO 溫度:液氮 |
培養(yǎng)方案A(默認) |
培養(yǎng)條件:
氣相:空氣,95%;CO2,5%, 溫度:37℃
|
推薦傳代比例 | 3×10^5-5×10^5cells/mL |
推薦換液頻率 | 2-3次/周 |
注意事項 | H22細胞是小鼠腹水瘤細胞,體外培養(yǎng)傳代4-5代左右,細胞活力會將低,狀態(tài)會變差,可通過腹水培養(yǎng)恢復細胞活力。該細胞為懸浮細胞,請注意離心收集細胞懸液;請勿直接倒掉細胞培養(yǎng)液。 |
背景描述 | H22細胞是分離自小鼠腹水,由大連醫(yī)科學院建立。 |
年齡(性別) | 不詳 |
組織來源 | 肝;肝癌 |
細胞類型 | 腫瘤細胞 |
腫瘤類型 | 肝膽癌細胞 |
STR鑒定
-
STR位點信息
18-3 11,17 6-7 13 5-5 14 X-1 25 1-2 18,19 7-1 24.2 8-1 17,18 1-1 15,16 19-2 13 15-3 19.3,20.3,25.3 12-1 17 6-4 15.3,16.3 4-2 19.3,20.3 3-2 13,14 2-1 9 13-1 16.2
11-2 16 17-2 13,15 -
STR鑒定圖
參考文獻
-
Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells(2019/10/31)
作者:Junyu Xiang, Ni Zhang, Juan Feng
期刊:Gastroenterology
DOI:10.1053/j.gastro.2019.10.025
影響因子 :29.400
-
Targeting RORγ inhibits the growth and metastasis of hepatocellular carcinoma(2024/02/02)
作者:Qianqian Liu, Junhua Wang, Huizi Sun
期刊:MOLECULAR THERAPY
DOI:10.1016/j.ymthe.2024.01.032
影響因子 :12.400
引用產(chǎn)品:CL-0341
-
Suppression of hepatocellular carcinoma by Ulva lactuca ulvan via gut microbiota and metabolite interactions(2023/04/17)
作者:Yinghui Qiu, Jingxiang Xu, Wei Liao
期刊:Journal of Advanced Research
DOI:10.1016/j.jare.2023.04.008
影響因子 :10.700
引用產(chǎn)品:CL-0341
-
Extracellular matrix modulating enzyme functionalized biomimetic Au nanoplatform-mediated enhanced tumor penetration and synergistic antitumor therapy for pancreatic cancer(2022/12/10)
作者:Xiaoyan Yang, Jinguo Zhang, Qiaomei Zhou
期刊:JOURNAL OF NANOBIOTECHNOLOGY
DOI:10.1186/s12951-022-01738-6
影響因子 :10.200
-
Nanoparticles prepared by polysaccharides extracted from Biyang floral mushroom loaded with resveratrol: Characterization, bioactivity and release behavior under in vitro digestion(2023/06/12)
作者:Keke Liu, Yongqi Liu, Jike Lu
期刊:FOOD CHEMISTRY
DOI:10.1016/j.foodchem.2023.136612
影響因子 :8.800
引用產(chǎn)品:CL-0341
-
The combination of Brassica rapa L. polysaccharides and cisplatin enhances the anti liver cancer effect and improves intestinal microbiota and metabolic disorders(2024/03/07)
作者:Hanrui Kong, Jun Yang, Xiaojing Wang
期刊:INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
DOI:10.1016/j.ijbiomac.2024.130706
影響因子 :8.200
引用產(chǎn)品:CL-0341
-
Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles(2022/07/06)
作者:Chenghua Song, Jia Zhang, Ruichao Wen
期刊:Materials Today Bio
DOI:10.1016/j.mtbio.2022.100350
影響因子 :8.200
-
Fluorinated carboxymethyl chitosan-based nano-prodrugs for precisely synergistic chemotherapy(2022/12/20)
作者:Chensong Zhang, Yining Song, Guoqing Yan
期刊:INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
DOI:10.1016/j.ijbiomac.2022.12.157
影響因子 :8.200
-
Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment(2023/11/04)
作者:Huawei Li, Jia You, Yuanfeng Wei
期刊:PHYTOMEDICINE
DOI:10.1016/j.phymed.2023.155189
影響因子 :7.900
引用產(chǎn)品:CL-0341
-
Assisting anti-PD-1 antibody treatment with a liposomal system capable of recruiting immune cells(2019/04/23)
作者:Boyang Zhou, Qiongchao Jiang, Xiaoyun Xiao
期刊:Nanoscale
影響因子 :6.700
引用產(chǎn)品:CL-0341
-
Lactose-modified enzyme-sensitive branched polymers as a nanoscale liver cancer-targeting MRI contrast agent(2022/12/12)
作者:Xiaoqin Zhang, Xiaoming Wang, Zhiqian Li
期刊:Nanoscale
影響因子 :6.700
引用產(chǎn)品:CL-0341
-
Astaxanthin slows down skeletal muscle atrophy in H22 tumor-bearing mice during sorafenib treatment by modulating the gut microbiota(2023/12/20)
作者:Pengfei Ren, Han Yue, Qingjuan Tang
期刊:Food & Function
影響因子 :6.100
引用產(chǎn)品:CL-0341
-
Protective effects of low-temperature plasma on cisplatin-induced nephrotoxicity(2021/12/14)
作者:Peng Guo,?Nan Zhang,?Juan Li?
期刊:Life Sciences
影響因子 :6.100
引用產(chǎn)品:CL-0341
-
Glycyrrhizic Acid-Based Liposome for Tumor-Targeted Delivery of Cantharidin(2024/01/02)
作者:Yuxiang Wang, Wenzhen Wang, Hailu Yao
期刊:ACS Applied Nano Materials
影響因子 :5.900
引用產(chǎn)品:CL-0341
-
Antitumor Activity of Carboxymethyl Pachymaran with Different Molecular Weights Based on Immunomodulatory and Gut Microbiota(2023/10/25)
作者:Yalin Zhao, Xi Feng, Lijia Zhang
期刊:Nutrients
影響因子 :5.900
引用產(chǎn)品:CL-0341
-
Ultrasound Molecular Imaging as a Potential Non-invasive Diagnosis to Detect the Margin of Hepatocarcinoma via CSF-1R Targeting(2020/07/14)
作者:Qiongchao Jiang, Yunting Zeng
期刊:FRONT BIOENG BIOTECH
影響因子 :5.700
引用產(chǎn)品:CL-0341
-
Ultrasound Molecular Imaging as a Potential Non-invasive Diagnosis to Detect the Margin of Hepatocarcinoma via CSF-1R Targeting(2020/7/14)
作者:Jiang Qiongchao, Zeng Yunting, Xu Yanni
期刊:Frontiers in Bioengineering and Biotechnology
影響因子 :5.700
引用產(chǎn)品:CL-0341
-
Engineering M1-derived nanovesicles loading with docosahexaenoic acid synergizes ferroptosis and immune activation for treating hepatocellular carcinoma(2023/03/07)
作者:Ming Meng, Xia Zhang, Qian Li
期刊:Cancer Nanotechnology
DOI:10.1186/s12645-023-00166-x
影響因子 :5.700
引用產(chǎn)品:CL-0341
-
Pathogenic Th17 cell-mediated liver fibrosis contributes to resistance to PD-L1 antibody immunotherapy in hepatocellular carcinoma(2024/02/13)
作者:Meiying Song, Luoyang Wang, Suli Jiang
期刊:INTERNATIONAL IMMUNOPHARMACOLOGY
DOI:10.1016/j.intimp.2024.111601
影響因子 :5.600
引用產(chǎn)品:CL-0341
-
Dietary supplementation of α-linolenic acid-rich flaxseed oil enhances anti-PD-1 protection against orthotopic hepatocellular carcinoma by reshaping gut homeostasis and improving anti-tumor immunity via gut-liver axis in mice(2024/04/01)
作者:Jian Liu, Yiwei Li, Wenke Shen
期刊:Journal of Functional Foods
影響因子 :5.600
引用產(chǎn)品:CL-0341
-
Astaxanthin exerts an adjunctive anti-cancer effect through the modulation of gut microbiota and mucosal immunity(2024/01/28)
作者:Pengfei Ren, Han Yue, Qingjuan Tang
期刊:INTERNATIONAL IMMUNOPHARMACOLOGY
DOI:10.1016/j.intimp.2024.111553
影響因子 :5.600
引用產(chǎn)品:CL-0341
-
Anti-tumor effect of Inonotus hispidus petroleum ether extract in H22 tumor-bearing mice and analysis its mechanism by untargeted metabonomic(2021/12/11)
作者:ZhijunLia,HaiyingBao
期刊:Journal Of Ethnopharmacology
影響因子 :5.400
引用產(chǎn)品:CL-0341
-
Aidi injection enhances the anti-tumor impact of doxorubicin in H22 tumor-containing mice(2022/12/05)
作者:Yuan Lu, Shuai Zhang, Xiaoqin Zhu
期刊:JOURNAL OF ETHNOPHARMACOLOGY
影響因子 :5.400
引用產(chǎn)品:CL-0341
-
Enhancing anti-tumor therapy with agmatine-cholesterol conjugate liposomes: in vitro and in vivo evidence(2023/09/27)
作者:Yanzhi Wang, Linchao Wang, Hanyue Chang
期刊:Drug Delivery and Translational Research
DOI:10.1007/s13346-023-01433-5
影響因子 :5.400
引用產(chǎn)品:CL-0341
-
Astaxanthin Augmented the Anti-Hepatocellular Carcinoma Efficacy of Sorafenib Through the Inhibition of the JAK2/STAT3 Signaling Pathway and Mitigation of Hypoxia within the Tumor Microenvironment(2023/12/07)
作者:Pengfei Ren, Qingjuan Tang, Xinjia He
期刊:MOLECULAR NUTRITION & FOOD RESEARCH
影響因子 :5.200
引用產(chǎn)品:CL-0341
-
Comparative study on the anti-tumor effect of steroids derived from different organisms in H22 tumor-bearing mice and analysis of their mechanisms(2023/12/13)
作者:Huimin Huo, Haiying Bao
期刊:EUROPEAN JOURNAL OF PHARMACOLOGY
DOI:10.1016/j.ejphar.2023.176269
影響因子 :5.000
引用產(chǎn)品:CL-0341
-
KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D(2021/07/02)
作者:Yonglan Wang, Kun Cao
期刊:Journal of Immunology Research
影響因子 :4.493
引用產(chǎn)品:CL-0341
-
CDK1-SRC Interaction-Dependent Transcriptional Activation of HSP90AB1 Promotes Antitumor Immunity in Hepatocellular Carcinoma(2023/11/10)
作者:Yijie Zhang, Dehui Yi
期刊:JOURNAL OF PROTEOME RESEARCH
DOI:10.1021/acs.jproteome.3c00379
影響因子 :4.400
引用產(chǎn)品:CL-0341
-
EGCG enhances cancer cells sensitivity under 60Coγ radiation based on miR-34a/Sirt1/p53(2019/09/05)
作者:Qiaozhen Kang, Xiaomiao Zhang, Nana Cao
期刊:Food And Chemical Toxicology
影響因子 :4.300
引用產(chǎn)品:CL-0341
-
Green Synthesis of Gold Nanoparticles from Polygahatous Polysaccharides and Their Anticancer Effect on Hepatic Carcinoma through Immunoregulation(2024/05/02)
作者:Maodong Leng, Huiqin Jiang, Sitong Zhang
期刊:ACS Omega
影響因子 :4.100
引用產(chǎn)品:CL-0341
-
Paeoniflorin increases the anti-tumor efficacy of sorafenib in tumor-bearing mice with liver cancer via suppressing the NF-κb/PD-l1 axis(2024/01/13)
作者:Junfei Li, Chenghui Zhu, Zengyu Zhang
期刊:Heliyon
DOI:10.1016/j.heliyon.2024.e24461
影響因子 :4.000
引用產(chǎn)品:CL-0341
-
Ajmalicine induces the pyroptosis of hepatoma cells to exert the antitumor effect(2023/12/08)
作者:Zhangchi Sun, Chenfang Ma, Xiaolan Zhan
期刊:JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
影響因子 :3.600
引用產(chǎn)品:CL-0341
-
Quercetin, the Ingredient of Xihuang Pills, Inhibits Hepatocellular Carcinoma by Regulating Autophagy and Macrophage Polarization(2022/12/20)
作者:Ruoxia Wu, Ting Zhou, Jiaqing Xiong
期刊:Frontiers in Bioscience-Landmark
影響因子 :3.100
-
Cistanche tubulosa Phenylethanoid Glycosides Induce Apoptosis of Hepatocellular Carcinoma Cells by Mitochondria-Dependent and MAPK Pathways and Enhance Antitumor Effect through Combination with Cisplatin:(2021/5/5)
作者:Pengfei Yuan, Changshuang Fu, Yi Yang
期刊:Integrative Cancer Therapies
影響因子 :2.900
引用產(chǎn)品:CL-0341
-
Radiosensitization potential of caffeic acid phenethyl ester and the long non-coding RNAs in response to 60Coγ radiation in mouse hepatoma cells(2020/12/24)
作者:Xiaomiao Zhang, Qiaozhen Kang, Zhenyu Ji
期刊:Radiation Physics and Chemistry
DOI:10.1016/j.radphyschem.2020.109326
影響因子 :2.900
引用產(chǎn)品:CL-0341
-
Effects of Sensitized Sorafenib with a Paeoniflorin and Geniposide Mixture on Liver Cancer via the NF-κB-HIF-2α-SerpinB3 Pathway(2022/10/15)
作者:Junfei Li, Xiaorong Zheng, Hongyan Zhang
期刊:Evidence-based Complementary and Alternative Medicine
影響因子 :2.650
引用產(chǎn)品:CL-0341
-
Antitumor Effects of Curcumin and Glycyrrhetinic Acid-Modified Curcumin-Loaded Cationic Liposome by Intratumoral Administration(2020/05/30)
作者:Mingxiang Chang, Meimei Wu, Hanmin Li
期刊:Evidence-Based Complementary and Alternative Medicine
影響因子 :2.650
引用產(chǎn)品:CL-0341
FAQs
Q:{{item.question}}
A:
產(chǎn)品資料
識別碼示意圖